BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Janssen Research & Development 

3210 Merryfield Row

San Diego  California  92121  U.S.A.
Phone: 858-450-2000 Fax: n/a


SEARCH JOBS


At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.

As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:

• cardiovascular and metabolism,
• immunology,
• infectious diseases and vaccines,
• neuroscience, and
• oncology.

We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.

We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.

Website: http://www.janssenrnd.com/our-company

Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research.
The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.

http://www.janssenlabs.com/about/overview


 Key Statistics


Email:
Ownership: Private

Web Site: Janssen Research & Development
Employees:
Symbol: 
 



Industry
Pharmaceutical






 Company News
Janssen Research & Development Submits New Drug Application For YONDELIS (trabectedin) To U.S. FDA For The Treatment Of Patients With Advanced Soft Tissue Sarcoma 11/25/2014 9:00:45 AM
Janssen Research & Development To Demonstrate Breadth Of Oncology Portfolio With 42 Clinical Data Presentations At The 2014 American Society of Hematology Annual Meeting 11/6/2014 10:28:30 AM
Janssen Research & Development Collaborates For Continued Evaluation Of Multidrug-Resistant Tuberculosis Treatment Regimens With SIRTURO® (bedaquiline) 11/6/2014 7:54:10 AM
Janssen Research & Development Release: IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted To The U.S. FDA For Waldenstrom's Macroglobulinemia 10/20/2014 7:23:33 AM
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), And Janssen Research & Development Announce Clinical Collaboration To Evaluate OPDIVO® (Nivolumab) And IMBRUVICA®(Ibrutinib) In Non-Hodgkin Lymphoma 10/13/2014 8:44:15 AM
Janssen Research & Development Demonstrates Continued Commitment To Combating Hepatitis C In European Patients With Data Presented At Viral Hepatitis Congress 10/10/2014 8:07:19 AM
Janssen Research & Development Release: ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis In Chemotherapy-Naive Men With Metastatic Castration-Resistant Prostate Cancer 9/29/2014 8:44:29 AM
Janssen Research & Development Expands EXPLORER Global Cardiovascular Research Program To Evaluate The Role Of XARELTO® In Addressing Critical Medical Needs 8/29/2014 11:05:38 AM
Janssen Research & Development Release: Data on XARELTO® At ESC Congress 2014 Hot Line Session Premieres First Prospective Study Of A Factor Xa Inhibitor In Elective Cardioversion 8/25/2014 8:46:58 AM
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Gains $20 Million Through Deal With Janssen Research & Development 8/21/2014 7:20:55 AM
1234567